Participating Organizations


The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for research, training, and education programs to enhance the health of individuals around the world. NHLBI is responsible for providing recommendations on CONNECTS developments and technical collaboration, as well as reviewing program milestones, objectives, and deliverables.

Administrative Coordinating Center (ACC)

The Administrative Coordinating Center (ACC) is run by RTI International with assistance from the Vanderbilt Institute for Clinical and Translation Research. The ACC supports the project management, administration, and coordination needs of CONNECTS and provides expertise in areas of study design and standardization of data collection. The ACC is responsible for tracking milestones and streamlining clinical trials operations, oversight, and safety.

RTI International
RTI International

RTI International is an independent, nonprofit institute that provides research, development, and technical services to government and commercial clients worldwide.
VICTR Vanderbilt Institute for Clinical and Translational Research
Vanderbilt Institute for Clinical and Translation Research (VICTR)

Vanderbilt Institute for Clinical and Translation Research (VICTR) is Vanderbilt's virtual home for clinical and translational research. The mission of the institute is to transform the way ideas and research discoveries make their way from origin to patient care.

Data Repository

NHLBI Biodata Catalyst

BioData Catalyst accelerates research and engagement to drive the discovery of new diagnostics, treatments, and prevention strategies. It supports data democratization, so NHLBI data is accessible and understandable by researchers and citizen scientists as they work to accelerate discovery.

Collaborating Networks and Groups

While these networks were originally created for different purposes, they have all refocused a substantial portion of their efforts to help conduct studies of COVID-19 therapeutics. The number of participating networks continues to grow, and are listed alphabetically.


The American Lung Association - Airways Clinical Research Centers (ACRC) Network is the nation’s largest not-for-profit network of clinical centers dedicated to asthma and COPD research working to positively impacts patients through large patient-focused clinical trials led by some of the best investigators nationwide.

The Cardiovascular Cell Therapy Research Network (CCTRN) is a network of physicians, scientists, and support staff dedicated to studying stem cell therapy for treating heart disease.

The Consortium Linking Oncology with Thrombosis (CLOT) encourages studies in selected cancer types that expand mechanistic investigation into the intersection between cancer and thrombotic pathways and applies mechanistic insights towards the identification and development of biomarkers of thrombotic risk or cancer progression.

The Consortium of Leaders in the study of Post-Traumatic Thromboembolism (CLOTT) focuses on the significance of incidentally discovered pulmonary thrombi after injury as well as the role of fibrinogen breakdown in the development of post-traumatic pulmonary embolism.

The goal of the Cardiothoracic Surgical Trials Network (CTSN) is to foster a culture of rigorous scientific comparisons and to promote the evaluation of newer surgical techniques, devices, and innovative pharmaceutical and bioengineered products directed at improving cardiovascular disease outcomes in adult populations.

The Clinical Trials Network (CTN) provides an enterprise in which the National Institute of Drug Abuse (NIDA), treatment researchers, and community-based service providers work toward new treatment options in community-level clinical practice.

The Heart Failure Clinical Research Network (HFN) is a clinical research initiative funded by NHLBI with the aim of improving our understanding of the condition and to discover innovative treatment options.

The I-SPY series of trials are changing the way new treatment are developed for breast cancer, helping make available new, better, and more personalized treatments, faster.

Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED) is a multi-center, randomized, double blind, active-control trial of high dose influenza vaccine compared to standard dose influenza vaccine for three seasons in adult participants with a history of myocardial infarction or heart failure.


The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) is an international comparative effectiveness study to determine the best way to manage stable ischemic heart disease.

IVY Network

The Influenza Vaccine Effectiveness in the Critically Ill (IVY) Network is a multi-site consortium of academic medical centers in the US funded by the Centers for Disease Control and Prevention (CDC) to conduct research on acute viral respiratory infections. 


The Laboratory for Clinical Biochemistry Research (LCBR) at the University of Vermont – Learner College of Medicine focuses on understanding risk factors for heart disease, stroke, venous thrombosis, obesity, diabetes, aging, and frailty using a wide variety of assays in population and family-based research settings.

Linking Investigations in Trauma and Emergency Services (LITES) is a research network for traumatic brain injury, whole blood, airway management, and emergency medical services.

The Montreal Heart Innovations Coordinating Center Network (MHICC) is dedicated to research in the fields of cardio-metabolic, renal, respiratory, oncology, cognitive function, gastro-intestinal, imaging, and precisions medicine.

Optumcare is a transformational force in the delivery of health care, integrating high-quality service across the ambulatory care continuum, offering local care powered by the strength of national resources, and delivering value-based care by scaling the most effective evidence-based medicine.

Pragmatic Critical Care Research Group: Improving the care of critically ill adults by studying common critical care practices in the environment in which they occur.


The National Patient-Centered Clinical Research Network (PCORnet) supports patient-centered and data enabled clinical research to deliver results more efficiently and with greater power than previously possible by harnessing the power of health information (EHRs, claims data, registry data).
Participating members of the PCORnet network:

The mission of INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) is to define optimal strategies for the management of HIV and other infectious diseases through a global clinical research network.

The OneFlorida Clinical Research Consortium, a statewide clinical research network and database, aims to unite researchers, clinicians, patients and stakeholders to address some of the nation’s biggest health challenges and serve as a resource for the state in facilitating health care research and improving health, health care and health policy.

Research Action for Health Network (REACHnet) is a partnership of health systems, academic centers, and public health organizations that constitute an innovative data network for conducting efficient, multi-site research.

The Stakeholders, Technology, and Research (STAR) Clinical Research Network robustly supports comparative effectiveness studies, pragmatic clinical trials, health system innovation, and the other research needs to improve health in the southern United States.

The Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury (PETAL) is a network of Clinical Centers (CC) and a Clinical Coordinating Center (CCC) funded by NHLBI to develop and conduct randomized controlled clinical trials to prevent or treat Acute Respiratory Distress Syndrome (ARDS).

The Precision Interventions for Severe and/or Exacerbation-Prone Asthma (PrecISE) Network is a network of medical centers, doctors, and scientists looking for better ways to treat teens and adults with severe asthma.

The Person Empowered Asthma Relief (PREPARE) study looks at two different ways to take medicines for rescue or quick relief of asthma symptoms among Latino or Hispanic patients and Black or African American patients.

The Pulmonary Trials Cooperative (PTC) was established by NHLBI to facilitate efficient “real world” research into chronic lung disease like interstitial lung disease, pulmonary hypertension, COPD, sarcoidosis, and obstructive sleep apnea.

Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE) is nationwide trial, led by the COPD Foundation Patient Powered Research Network, to compare azithromycin and roflumilast to learn which works best for which patients.

REMAP-CAP is a randomized, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia that can adapt to efficiently evaluate multiple treatment options for patients who are critically ill.

The Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) is funded by the National Institute for Neurological Disorders and Stroke (NINDS), the National Center for Advancing Translational Science (NCATS), and NHLBI with the goal of improving the outcomes of patients with neurologic, cardiac, respiratory and hematologic emergencies by identifying effective treatments given in the earliest stages of care.

The Trans-Agency Consortium for Trauma-Induced Coagulopathy (TACTIC) was assembled to study coagulation in trauma patients.

The Thrombolysis in Myocardial Infarction (TIMI) Study Group provides robust expertise in the key aspects of a clinical trial including academic leadership, global management, biostatistics, clinical event adjudication, safety desk, medical hotline, and core laboratories.

The Venous thromboEmbolism Network United States (VENUS) is a collaborative US research network organized to initiate and implement collaborative, multi-institutional, investigator-initiated clinical trials and/or other scientific research projects focused on thrombotic disorders.
Participating members of the VENUS network:

RAPID COVID COAG is a network of over 40 sites in the US, Canada, Ireland, Brazil, Saudi Arabia, and Serbia conducting a parallel pragmatic multi-center open-label randomized controlled trial to determine the effect of therapeutic anticoagulation compared to standard care in hospitalized patients with COVID-19 and an elevated D-dimer.